GSK delivers solid 2025 results, reaffirms growth outlook for 2026 Proactive uses images sourced from Shutterstock Specialty Medicines drive strong sales as company maintains guidance and raises dividend GSK PLC (LSE:GSK, NYSE:GSK) reported a 7% rise in sales for 2025 to £32.7 billion, led by strong performance in Specialty Medicines, which grew 17% to £13.5 billion. Sales in HIV, Oncology and Respiratory, Immunology & Inflammation divisions all posted double-digit gains. Vaccines brought in £9.2 billio ...